跳至主要内容
临床试验/NCT03472651
NCT03472651已完成1 期

Interventional, Randomized, Single Dose, Open-label, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) - in Fasted and Fed Conditions

H. Lundbeck A/S1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年5月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
60
试验地点
1
主要终点
AUC0-72h: flupentixol

研究概览

简要总结

The purpose of this study is to establish bioequivalence of flupentixol/meltracen, between a new film-coated tablet formulation and the marketed coated tablet formulation (Deanxit®), administered single dose in fasted and fed condition

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy men and women ≥18 and ≤55 years of age with a body mass index (BMI) of ≥ 18.5 and ≤ 28 kg/m
  • Women must be non-pregnant and non-lactating

排除标准

  • 未提供

结局指标

主要结局

AUC0-72h: flupentixol

时间窗: from zero to 72 hours post-dose

the area under the flupentixol plasma concentration-time curve

AUC0-72h: melitracen

时间窗: from zero to 72 hours post-dose

the area under the melitracen plasma concentration-time curve

Cmax: melitracen

时间窗: from zero to 72 hours post-dose

maximum observed concentration of melitracen

Cmax: flupentixol

时间窗: from zero to 72 hours post-dose

maximum observed plasma concentration of flupentixol

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验